BiotechTube
4D Path

4D Path

Cambridge, United States· Est.
4dpath.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

4D Path is a private, pre-revenue diagnostics company founded in 2017 and headquartered in Cambridge, Massachusetts. The company has developed the QPOR™ Platform, a proprietary AI/ML platform that extracts novel biological signatures from standard pathology slides to predict therapeutic response across multiple cancer types and drug classes. With FDA Breakthrough Device Designation for breast cancer diagnostics and validation studies with leading cancer centers, 4D Path is positioning its technology as a tool for both clinical decision support and biopharma drug development partnerships.

Oncology

Technology Platform

QPOR™ Platform: An AI/ML cloud-based platform that applies statistical physics and deep learning to digitized H&E-stained biopsy images to directly quantify cell cycle deregulations and tumor microenvironment dynamics, generating 29+ continuous-scale indices to predict therapy response.

Opportunities

The platform's therapy- and tumor-agnostic nature allows it to address a vast market across multiple solid tumors and drug classes.
The use of standard H&E slides enables rapid, low-cost integration into global clinical workflows, bypassing the need for expensive ancillary testing and facilitating widespread adoption.

Risk Factors

Key risks include the need for large-scale prospective clinical validation to prove superior predictive value, navigating complex FDA regulatory pathways for software as a medical device, and securing reimbursement in a competitive AI diagnostics landscape where market adoption is not guaranteed.

Competitive Landscape

4D Path competes in the growing AI-powered digital pathology and computational biomarker space. Competitors include companies like PathAI, Paige.AI, and others developing algorithms for diagnosis and prognosis. 4D Path differentiates by focusing specifically on quantifying cell cycle dynamics and the collective tumor state from H&E, rather than just identifying patterns or inferring from genomic proxies.

More companies in Diagnostics & Precision Medicine →More companies in United States →